Gu Liangyou, Li Hongzhao, Chen Luyao, Ma Xin, Gao Yu, Li Xintao, Zhang Yu, Fan Yang, Zhang Xu
Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing 100853, P.R. China.
Oncotarget. 2015 Oct 20;6(32):32545-60. doi: 10.18632/oncotarget.5324.
This is a systematic review of studies investigating the prognostic value of different microRNAs (miRs) in renal cell carcinoma (RCC). Twenty-seven relevant studies were identified, with a total of 2578 subjects. We found that elevated expression of miR-21, miR-1260b, miR-210, miR-100, miR-125b, miR-221, miR-630, and miR-497 was associated with a poor prognosis in RCC patients. Conversely, decreased expression of miR-106b, miR-99a, miR-1826, miR-215, miR-217, miR-187, miR-129-3p, miR-23b, miR-27b, and miR-126 was associated with a worse prognosis. We performed meta-analyses on studies to address the prognostic value of miR-21, miR-126, miR-210, and miR-221. This revealed that elevated miR-21 expression was associated with shorter overall survival (OS; hazard ratio [HR], 2.29; 95% confidence interval [CI], 1.28-4.08), cancer specific survival (CSS; HR, 4.16; 95% CI, 2.49-6.95), and disease free survival (DFS; HR, 2.15; 95% CI, 1.16-3.98). The decreased expression of miR-126 was associated with shorter CSS (HR, 0.35; 95% CI, 0.15-0.85), OS (HR, 0.45; 95% CI, 0.30-0.69), and DFS (HR 0.30; 95% CI, 0.18-0.50). Our comprehensive systematic review reveals that miRs, especially miR-21 and miR-126, could be promising prognostic markers and useful therapeutic targets in RCC.
这是一项对研究不同微小RNA（miR）在肾细胞癌（RCC）中预后价值的研究的系统评价。共鉴定出27项相关研究，涉及2578名受试者。我们发现，miR-21、miR-1260b、miR-210、miR-100、miR-125b、miR-221、miR-630和miR-497表达升高与RCC患者预后不良相关。相反，miR-106b、miR-99a、miR-1826、miR-215、miR-217、miR-187、miR-129-3p、miR-23b、miR-27b和miR-126表达降低与预后较差相关。我们对研究miR-21、miR-126、miR-210和miR-221预后价值的研究进行了荟萃分析。结果显示，miR-21表达升高与总生存期（OS；风险比[HR]，2.29；95%置信区间[CI]，1.28 - 4.08）、癌症特异性生存期（CSS；HR，4.16；95%CI，2.49 - 6.95）和无病生存期（DFS；HR，2.15；95%CI，1.16 - 3.98）缩短相关。miR-126表达降低与CSS缩短（HR，0.35；95%CI，0.15 - 0.85）、OS缩短（HR，0.45；95%CI，0.30 - 0.69）和DFS缩短（HR 0.30；95%CI，0.18 - 0.50）相关。我们全面的系统评价表明，miR，尤其是miR-21和miR-126，可能是RCC中有前景的预后标志物和有用的治疗靶点。
